Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence.
about
Lyn, a Src family kinase, regulates activation of epidermal growth factor receptors in lung adenocarcinoma cellsImpact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trialsSomatic mutations of the epidermal growth factor receptor and non-small-cell lung cancerEGFR targeted therapy in non-small cell lung cancer: potential role of cetuximabEpidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer: results and open issuesMucinous differentiation correlates with absence of EGFR mutation and presence of KRAS mutation in lung adenocarcinomas with bronchioloalveolar featuresOncogenic transformation by inhibitor-sensitive and -resistant EGFR mutantsGefitinib in the treatment of nonsmall cell lung cancer with activating epidermal growth factor receptor mutationMolecular pathology of lung cancer: key to personalized medicine.Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer.Good clinical response to gefitinib in a non-small cell lung cancer patient harboring a rare somatic epidermal growth factor gene point mutation; codon 768 AGC > ATC in exon 20 (S768I).The role of surgical intervention in lung cancer with carcinomatous pleuritisTherapeutic value of EGFR inhibition in CRC and NSCLC: 15 years of clinical evidenceEpidermal growth factor receptor in non-small cell lung cancerKRAS mutant allele-specific imbalance in lung adenocarcinomaLoss of activating EGFR mutant gene contributes to acquired resistance to EGFR tyrosine kinase inhibitors in lung cancer cellsA trial-based cost-effectiveness analysis of erlotinib alone versus platinum-based doublet chemotherapy as first-line therapy for Eastern Asian nonsquamous non-small-cell lung cancerMET Gene Amplification and MET Receptor Activation Are Not Sufficient to Predict Efficacy of Combined MET and EGFR Inhibitors in EGFR TKI-Resistant NSCLC CellsBIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutationsClinical benefit of readministration of gefitinib for initial gefitinib-responders with non-small cell lung cancer.Epidermal growth factor receptor (EGFR) gene copy number detection in non-small-cell lung cancer; a comparison of fluorescence in situ hybridization and chromogenic in situ hybridization.Frequently increased epidermal growth factor receptor (EGFR) copy numbers and decreased BRCA1 mRNA expression in Japanese triple-negative breast cancersPhase II study of nedaplatin and irinotecan with concurrent thoracic radiotherapy in patients with locally advanced non-small-cell lung cancer.Morphologic features of adenocarcinoma of the lung predictive of response to the epidermal growth factor receptor kinase inhibitors erlotinib and gefitinib.Relationship between EGFR expression, copy number and mutation in lung adenocarcinomasEnhancement of gefitinib-induced growth inhibition by Marsdenia tenacissima extract in non-small cell lung cancer cells expressing wild or mutant EGFR.Critical appraisal of the role of gefitinib in the management of locally advanced or metastatic non-small cell lung cancerActivating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitorsChromosomal and genomic changes in lung cancer.Genetic and epigenetic tumor suppressor gene silencing are distinct molecular phenotypes driven by growth promoting mutations in nonsmall cell lung cancer.CRIPTO1 expression in EGFR-mutant NSCLC elicits intrinsic EGFR-inhibitor resistance.Investigation of the epidermal growth factor receptor mutation rate in non-small cell lung cancer patients and the analysis of associated risk factors using logistic regression.Mutation detection of epidermal growth factor receptor and KRAS genes using the smart amplification process version 2 from formalin-fixed, paraffin-embedded lung cancer tissueRapid detection of epidermal growth factor receptor mutations with multiplex PCR and primer extension in lung cancer.Copper transporter CTR1 expression and tissue platinum concentration in non-small cell lung cancer.Emerging role of gefitinib in the treatment of non-small-cell lung cancer (NSCLC).Aberrations in the epidermal growth factor receptor gene in 958 patients with diverse advanced tumors: implications for therapy.Clinical utility of erlotinib for the treatment of non-small-cell lung cancer in Japanese patients: current evidenceA prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER)Combining erlotinib and cetuximab is associated with activity in patients with non-small cell lung cancer (including squamous cell carcinomas) and wild-type EGFR or resistant mutations.
P2860
Q24309725-ADE5348F-2087-4E22-9305-5AA3AB8EE937Q24625201-6DF0C971-AFAC-4D40-A59D-EBB04C152693Q24648133-D35267B8-1EF6-4894-995F-A16C1D8509F9Q24652337-2EA4D5B0-36B1-4ADA-B435-BD8B863FE80FQ24653036-A2D7EE31-67D8-4C95-875E-ADE2ECBEB3F6Q24683814-A654E805-6BAB-43F9-BF5B-809F267AA0F5Q24810573-46C33B1C-3A12-40C3-9625-F7D5DFF711C1Q26739096-573F8B8B-774E-496D-AB75-0E1E6FC5E366Q27691299-D0B56875-D0E2-4C75-A632-5EC4D9CCCB1EQ27851396-FAFFCECF-BCDC-48C2-9150-6C48F169E54DQ27851566-89445884-5B20-479E-8DC4-23D762801A94Q28068169-5B269402-1E44-477D-AD25-6C108BD897B2Q28071772-365A518F-292E-48F3-84B4-BF89F80274F9Q28088636-0D230E1A-2692-411A-9BD2-390A97F7C400Q28242884-B00D9698-6686-4184-B996-BCF4EE2AC40CQ28481370-005DC958-4E8E-481D-B158-15456808AF38Q28487847-00753EA9-2B90-426A-A18F-D02317B4224BQ28551045-472D21BF-8582-473E-A265-2A682A8AA227Q28756824-9788BF9E-57A2-4C30-8D98-E417568516FCQ33279462-39F7D3FE-B9CE-4ABD-AC0D-4F64691AAFD6Q33302191-AC838F78-6D4D-45A1-AD25-E7D414DEF755Q33379276-EF8B4CA8-0B31-459A-892B-7B62EE39F1A6Q33392253-B219AFC1-95E8-4E48-8D0C-D5836697647DQ33594324-F3C9129C-38AF-418A-B756-A8F8BD528234Q33634703-25B4169B-02C4-4000-9EC8-2E1ED12D0069Q33693476-BD7B9388-47F4-4082-8FDE-B7CA87BF93C3Q33710152-FD8E6020-ABC9-41D6-8DD3-5ABEC33B3401Q33769838-8B0AEC6F-2DA6-48F7-A1CE-3B08B9EE511EQ33781119-00E63918-A5DA-4084-A936-EC4ED6E14B50Q33807653-A8F7E1A8-12A4-4117-B001-2F265B1AA39EQ33808203-9D47E25C-D33E-41FE-BFFA-6C951B97E54AQ33844140-F56A4A1C-3E82-4D24-9B19-7E4653716209Q33856261-B87BAB3C-857F-42D9-ADA4-1EDD812411F3Q33872030-C3BA92DD-47A1-4FA5-B39A-DD56D62A5D36Q33875938-867E34DB-8FAA-4A76-9F8C-927688866F71Q33892582-658C3826-928E-4AE3-B5AF-41D8F20059D4Q33947959-E4DF714E-AF3D-419E-AEE6-11D2BC854DC2Q34011705-6AF05C26-C047-4948-8242-3EE39D04FBBBQ34041754-61361C6F-AF67-4324-9D88-87110FDDDF65Q34066159-F841B58A-1A98-46F8-B665-7F24C82F94B6
P2860
Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence.
description
2005 nî lūn-bûn
@nan
2005 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Mutations of the epidermal gro ...... with postoperative recurrence.
@ast
Mutations of the epidermal gro ...... with postoperative recurrence.
@en
Mutations of the epidermal gro ...... with postoperative recurrence.
@nl
type
label
Mutations of the epidermal gro ...... with postoperative recurrence.
@ast
Mutations of the epidermal gro ...... with postoperative recurrence.
@en
Mutations of the epidermal gro ...... with postoperative recurrence.
@nl
prefLabel
Mutations of the epidermal gro ...... with postoperative recurrence.
@ast
Mutations of the epidermal gro ...... with postoperative recurrence.
@en
Mutations of the epidermal gro ...... with postoperative recurrence.
@nl
P2093
P356
P1476
Mutations of the epidermal gro ...... with postoperative recurrence.
@en
P2093
Hideki Endoh
Masayuki Shinoda
Shoichi Mori
Shunzo Hatooka
Takashi Takahashi
Takayuki Kosaka
Tetsuya Mitsudomi
Toyoaki Hida
Yoshitsugu Horio
P304
P356
10.1200/JCO.2005.00.992
P407
P577
2005-02-28T00:00:00Z